BeatO – India’s digital care ecosystem for chronic condition management – has raised USD 5.7 million in funding led by US-based venture capital firm, W Health Ventures.
The funding also saw participation from e-pharmacy Unicorn PharmEasy (a Threpsi Solutions Pvt Ltd brand), Merisis VP and existing investors Orios VP, Leo Capital, and others.
With this new funding, BeatO has raised more than USD 10 million over the last year across its Series A and Pre-series B rounds. The fresh funds will be utilized across two key areas – growth in subscriber base across multiple channels and geographies, and product enhancement to provide care for other cardiometabolic conditions.
Commenting on the new funding, Gautam Chopra, Co-Founder & CEO – BeatO, said, “Diabetes and Hypertension have been the major killers in this pandemic. With our holistic tech-based solution that supports end to end management for these conditions, we have a proven product and technology with a highly engaged and rapidly growing member base. We welcome our new partners in our exciting journey as we continue to address this large global problem and positively impact millions of lives.”
“We’re impressed with BeatO’s unparalleled patient experience and outstanding clinical results. The Company’s exponential growth is driven by its ability to transcend geographical and socio-economic barriers. We’re thrilled to join the BeatO team in this exciting journey of making affordable, accessible, and world-class diabetes care a reality for millions of people across the world,” added Dr. Pankaj Jethwani, Executive Vice President at W Health Ventures.
